Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perhexiline in diabetic or pre-diabetic patients with chronic cardiac disease
ACTRN12615000497505Phase 4Recruiting
- Sponsor
- Cardiology Department, The Queen Elizabeth Hospital
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of perhexiline in type 2 diabetes mellitus (T2DM), prediabetes and cardiac disease, sponsored by Cardiology Department, The Queen Elizabeth Hospital. Primary endpoint: Change in platelet thioredoxin-interacting protein content. Started Apr 2014; status: recruiting.
02
Drugs
perhexiline
03
Conditions
type 2 diabetes mellitus (T2DM)prediabetescardiac disease
Beyond the preview
Go deeper on ACTRN12615000497505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000497505.